Specific-class Skin Side-effects of Drugs Might Compromise Blinding in Randomized Controlled Trials
Keywords:blinding, randomized controlled trial, side effects
Abstract is missing (Short communication)
Bello S, Moustgaard H, Hróbjartsson A. Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials. J Clin Epidemiol 2017; 81: 42-50.
https://doi.org/10.1016/j.jclinepi.2016.08.002 DOI: https://doi.org/10.1016/j.jclinepi.2016.08.002
Savović J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 2012; 157: 429-438.
https://doi.org/10.7326/0003-4819-157-6-201209180-00537 DOI: https://doi.org/10.7326/0003-4819-157-6-201209180-00537
Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PloS Med 2006; 3: e425.
https://doi.org/10.1371/journal.pmed.0030425 DOI: https://doi.org/10.1371/journal.pmed.0030425
Hróbjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol 2014; 43: 1272-1283.
https://doi.org/10.1093/ije/dyu115 DOI: https://doi.org/10.1093/ije/dyu115
Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist 2021; 26: e316-e326.
https://doi.org/10.1002/onco.13552 DOI: https://doi.org/10.1002/onco.13552
Khalil S, Bardawil T, Stephan C, Darwiche N, Abbas O, Kibbi AG, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat 2017; 28: 684-696.
https://doi.org/10.1080/09546634.2017.1309349 DOI: https://doi.org/10.1080/09546634.2017.1309349
Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective outcomes in randomized clinical trials: definitions differed in methods publications and were often absent from trial reports. J Clin Epidemiol 2014; 67: 1327-1334.
https://doi.org/10.1016/j.jclinepi.2014.06.020 DOI: https://doi.org/10.1016/j.jclinepi.2014.06.020
Ueyama A, Yamamoto M, Tsujii K, Furue Y, Imura C, Shichijo M, et al. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol 2014; 41: 135-143.
https://doi.org/10.1111/1346-8138.12367 DOI: https://doi.org/10.1111/1346-8138.12367
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372: 735-746.
https://doi.org/10.1056/NEJMoa1404710 DOI: https://doi.org/10.1056/NEJMoa1404710
Leducq S, Samimi M, Bernier C, Soria A, Amsler E, Staumont-Sallé D, et al. Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: a randomized, controlled trial. J Am Acad Dermatol 2020; 82: 240-243.
https://doi.org/10.1016/j.jaad.2019.07.097 DOI: https://doi.org/10.1016/j.jaad.2019.07.097
Howick J, Webster R, Kirby N, Hood K. Rapid overview of systematic reviews of nocebo effects reported by patients taking placebos in clinical trials. Trials 2018; 19: 674.
https://doi.org/10.1186/s13063-018-3042-4 DOI: https://doi.org/10.1186/s13063-018-3042-4
Golder S, Loke Y, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol 2008; 61: 440-448.
https://doi.org/10.1016/j.jclinepi.2007.06.005 DOI: https://doi.org/10.1016/j.jclinepi.2007.06.005
Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009; 169: 1756-1761.
https://doi.org/10.1001/archinternmed.2009.306 DOI: https://doi.org/10.1001/archinternmed.2009.306
How to Cite
Copyright (c) 2023 Giao Do-Pham, Annabel Maruani, Sophie Leducq, Bruno Giraudeau, Olivier Chosidow
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.